SEC Form 4 · accession 0001179110-17-005728
Assertio Therapeutics, Inc · ASRT
Statement of changes in beneficial ownership, as filed. Original on EDGAR ↗
Reporting owner
Arthur J Higgins
Officer — President and CEO · Director
Period of report
Mar 31, 2017
Accepted (ET)
Apr 4, 2017 · 8:32 pm EDT
Rule 10b5-1 plan
unknown — predates the checkbox
Issuer CIK
0001005201
Table I — non-derivative securities
No Table I lines on this filing.
Table II — derivative securities
| Security | Conv. / exercise price | Date | Code | Shares | A/D | Exercisable | Expires | Underlying | Underlying shares | Owned after | D/I |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Stock OptionsF1 | $12.55 | Mar 31, 2017 | A | 315,884 | A | — | Mar 31, 2027 | Common Stock | 315,884 | 315,884 | D |
| Restricted Stock UnitsF2,F3 | — | Mar 31, 2017 | A | 139,442 | A | — | — | Common Stock | 139,442 | 139,442 | D |
Explanation of responses
- F1Exercisable with respect to 12.5% of the underlying shares on September 28, 2017, and in 42 equal monthly installments thereafter, such that the stock options will be fully vested and exercisable on March 28, 2021.
- F2Each restricted stock unit represents the contingent right to receive one share of common stock upon vesting of the unit.
- F3These restricted stock units are scheduled to vest 25% on December 1, 2017, 25% on December 1, 2018, 25% on December 1, 2019 and 25% on December 1, 2020, assuming continued employment through the applicable vesting date.